BioNTech Signed an Exclusive License and Collaboration Agreements with DualityBio for Two ADC Therapies to Treat Solid Tumors
Shots:
- DualityBio will receive $170M up front for both assets (DB-1303 & DB-1311), ~$1.5B in additional development, regulatory & commercial milestones along with royalties on net sales for both ADC assets
- BioNTech received exclusive licenses from DualityBio for 2 ADC assets (DB-1303 & DB-1311) directed against targets expressed in a broad range of human cancers & will obtain commercial rights globally (excl. Mainland China, Hong Kong Special Administrative Region & Macau Special Administrative Region)
- DualityBio will hold commercial rights for Mainland China, Hong Kong Special Administrative Region & Macau Special Administrative Region & also get the right to exercise a co-development cost and profit/loss sharing option for DB-1311 & co-promotion option for the US market
Ref: biontech and dualitybio | Image: biontech and dualitybio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
